Anticholinergic Burden in Older Adults With Overactive Bladder
Overactive bladder (OAB) is common in later life and is defined by urinary urgency, usually with increased daytime frequency and nocturia, with or without urgency urinary incontinence. Antimuscarinic medicines can reduce these symptoms, yet their effects add to the wider “anticholinergic burden” created by many prescription and over-the-counter products.
A systematic review of this issue must look beyond a single bladder medicine. Older adults may also use antidepressants, antihistamines, sleep medicines, antipsychotics or treatments for Parkinson’s disease, each contributing to anticholinergic exposure. The clinical question is therefore whether symptom relief justifies the combined risks, particularly for people with frailty, cognitive impairment or multiple chronic conditions.
Why Anticholinergic Burden Matters
Anticholinergic drugs block acetylcholine, a neurotransmitter involved in bladder contraction, salivation, bowel function, vision and cognitive processing. For OAB, this action can reduce involuntary detrusor activity and improve urgency. Common agents include oxybutynin, solifenacin, tolterodine, darifenacin and fesoterodine.
The same pharmacological effect can cause dry mouth, constipation, blurred vision, tachycardia and difficulty emptying the bladder. In older adults, these adverse effects may contribute to falls, dehydration, dental disease and reduced independence. A person waking several times at night to void may be especially vulnerable if medication-related dizziness or blurred vision is added to nocturia.
Anticholinergic burden is usually cumulative rather than attributable to one product alone. A low-dose bladder treatment may appear reasonable when reviewed in isolation, while the total regimen becomes concerning after an antihistamine, tricyclic antidepressant or sedating medicine is included.
What A Systematic Review Should Measure
A robust review should define its population clearly, usually adults aged 65 years and over with OAB, urgency urinary incontinence or related lower urinary tract symptoms. It should distinguish community-dwelling people from residents of aged-care facilities, because prescribing patterns, frailty and monitoring differ substantially between these groups.
Relevant outcomes include cognitive decline, delirium, falls, fractures, hospitalisation, constipation, urinary retention, dry mouth, treatment discontinuation and quality of life. Bladder-specific outcomes remain important: urgency episodes, incontinence episodes, nocturia, voiding frequency and patient-reported improvement should be weighed alongside harms.
The evidence base is often heterogeneous. Randomised trials may show short-term symptom benefits but exclude people with dementia, advanced frailty or several comorbidities. Cohort and case-control studies better reflect real-world prescribing, although confounding by illness severity can make it difficult to determine whether harm comes from the drug, the underlying condition or both.
Cognitive And Functional Risks In Later Life
Cognitive concerns receive particular attention because acetylcholine supports memory and attention. Observational research has associated cumulative exposure to strong anticholinergic medicines with cognitive impairment and, in some studies, dementia. These findings do not prove that every antimuscarinic causes dementia, but they support cautious prescribing and regular review.
Oxybutynin is often highlighted because it can cross the blood–brain barrier more readily than some newer agents. Formulation, dose, age, kidney function and overall medication load all influence individual risk. A medicine that was tolerated at 68 may become problematic at 82 after weight loss, renal impairment or the development of mild cognitive impairment.
Functional effects can be just as important as cognitive outcomes. Constipation can worsen urinary urgency and discomfort, while sedation, poor vision and postural symptoms may increase falls. For an older person in Melbourne or Perth who lives alone, a fall or episode of confusion may have greater consequences than a modest reduction in daily urgency.
Reviewing Medicines Across The Whole Regimen
Medication reconciliation should include prescriptions, pharmacy purchases, complementary products and medicines supplied by different clinicians. In Australia, a GP, community pharmacist and residential aged-care team may each hold part of the medication history. The Pharmaceutical Benefits Scheme can make regular medicines accessible, but subsidised supply does not remove the need to assess cumulative adverse effects.
Prescribers can use anticholinergic risk scales as prompts rather than absolute decision tools. Different scales assign different weights to medicines, and they may not fully capture dose, duration, serum concentration or a person’s sensitivity. A structured review should ask whether each drug remains necessary, whether a safer alternative exists and whether the OAB diagnosis has been reassessed.
A gradual deprescribing plan may be appropriate when harms outweigh benefits. Abruptly stopping some medicines can cause rebound symptoms or withdrawal, so changes should be individualised. Monitoring should cover continence, sleep, bowel function, cognition, dizziness and the person’s ability to manage daily activities.
| Clinical issue | Why it matters in older adults | Practical review point |
|---|---|---|
| Cognitive impairment or delirium | Anticholinergic exposure may worsen attention and memory | Check cognition and avoid unnecessary high-risk agents |
| Constipation | Can increase discomfort, urgency and urinary symptoms | Review bowel medicines, fluid intake and diet |
| Falls or dizziness | Nocturia combined with sedation or blurred vision raises injury risk | Assess night-time mobility and orthostatic symptoms |
| Urinary retention | Reduced bladder contractility can aggravate incomplete emptying | Measure post-void residual when clinically indicated |
| Dry mouth | May impair eating, speech, oral health and medication adherence | Ask about dental problems and hydration |
| Treatment benefit | Symptom improvement may be small or short-lived | Continue only when meaningful benefit is documented |
Non-Drug Care And Safer Treatment Pathways
Behavioural treatment should be part of OAB management, especially when medication risks are substantial. Bladder training, timed voiding, pelvic floor muscle training, appropriate fluid management and treatment of constipation may reduce urgency and incontinence. Excessive fluid restriction is generally unhelpful, particularly during Australian heatwaves or for people taking diuretics.
Lifestyle advice needs to be practical rather than prescriptive. Reducing caffeine, including strong coffee and energy drinks, may help some people, while evening alcohol can worsen nocturia and sleep disruption. Someone trying to stay active with two dogs may benefit from planning nearby toilets and predictable walking routes; guidance on walking two dogs safely is separate from continence care, but illustrates how daily routines can be adapted without abandoning activity.
When medication is needed, a beta-3 adrenergic agonist such as mirabegron may be considered as an alternative to an antimuscarinic for suitable patients. Blood pressure, cardiovascular history, renal function and drug interactions require review, and access and cost may vary under Australian prescribing arrangements. Specialist options, including intradetrusor botulinum toxin or neuromodulation, may be considered for refractory symptoms.
Distinguishing OAB From Other Urinary Conditions
Urgency and frequency do not always indicate uncomplicated OAB. Urinary tract infection, haematuria, diabetes, excessive evening fluids, sleep apnoea, oedema, diuretic timing and incomplete bladder emptying can produce similar symptoms. A medication review should therefore sit alongside urinalysis when indicated, a symptom diary, physical examination and assessment of post-void residual in selected patients.
Bladder pain, recurrent infection or pelvic discomfort may point towards another diagnosis. Contemporary discussion of bladder pain syndrome is useful because pain is not a typical defining feature of uncomplicated OAB. Treating presumed urgency with escalating anticholinergic doses can delay more appropriate assessment.
A careful history also prevents inappropriate transfer of evidence between age groups and conditions. For example, long-term outcomes after hypospadias repair concern a paediatric urological pathway, not the usual evaluation of an older adult with new urgency. Clear diagnostic boundaries help ensure that anticholinergic exposure is addressed in the right clinical context.
Australian Implications For Prescribing And Follow-Up
Australian care is often GP-led, with referral to continence nurses, urologists, geriatricians or pelvic floor physiotherapists when symptoms persist. Access can be straightforward in Sydney, Brisbane or Adelaide but more limited in regional and remote communities, where travel, telehealth availability and local pharmacy stock may affect follow-up. A review strategy should account for these practical differences.
The Therapeutic Goods Administration, Australian prescribing information and local medicines formularies provide safety information, while the PBS influences which treatments are affordable and routinely used. Patients may still face co-payments, dispensing gaps or out-of-pocket costs, so the most clinically suitable alternative also needs to be financially realistic. Cost discussions should be private and non-judgemental; links about unrelated consumer finance, such as how card interest is calculated, should not be substituted for a pharmacist’s explanation of medicine costs.
Follow-up is essential after starting, switching or deprescribing treatment. A review within several weeks can assess symptom change, blood pressure where relevant, bowel function, cognition, falls and adherence. Longer-term review should confirm that the medicine continues to provide a meaningful benefit rather than remaining on the repeat list by default.
Interpreting The Evidence For Clinical Decisions
A systematic review can clarify associations, identify medicines with greater theoretical or observed risk and expose gaps in research. It cannot replace shared decision-making. An older person with severe urgency who remains independent on a low-risk, closely monitored regimen may reasonably choose treatment, while another with recurrent delirium may prioritise deprescribing even if symptoms return.
Evidence quality should be judged carefully. Studies relying on prescription records may measure exposure without confirming whether medicines were taken. Cognitive outcomes may be assessed differently across studies, and short follow-up may miss delayed harms. Reviews should report these limitations rather than presenting an anticholinergic burden score as a precise prediction of an individual’s future.
The most defensible clinical approach combines symptom benefit, total medication exposure, vulnerability, alternatives and patient goals. Documenting the rationale supports continuity between Australian GPs, pharmacists, specialists and aged-care clinicians. It also makes future reassessment easier when health status or treatment priorities change.
Older adults with OAB deserve treatment that improves daily life without creating avoidable cognitive, bowel, cardiovascular or falls-related problems. Clinicians can begin with a complete medication history, investigate alternative causes of urinary symptoms, use non-drug strategies and reassess antimuscarinic therapy at every meaningful transition in care. Patients and carers should raise new confusion, constipation, dizziness, retention or falls promptly with a GP or pharmacist so that the balance between continence and safety can be reviewed.